One of the longest, established, privately held biotech companies, founded in 1978.
Leading global provider of high-quality raw materials to the in-vitro diagnostic industry and research laboratories.
ISO 13485:2016 registered.
Joined the Biosynth Group to form the biologics division in May 2022.
KEY CAPABILITIES
First to market proteins and monoclonal antibodies for the new emerging viruses, eg. Dengue, Chikungunya and Zika, Sars, Covid -19 and VEEV virus.
Wide range of well-established products for chemiluminscence, ELISA, lateral flow and other immunoassay formats.
Custom manufacture of antibodies and recombinant antigens under ISO 13485:2016 conditions
OUR GOAL
To maintain our position as the leading global provider of high-quality and esoteric biological raw materials to the in-vitro diagnostic industry.
To enable our customers to bring ground-breaking technology to the market faster allowing cost-effective and efficient patient management at the point of impact.
